Multicenter, Prospective, Randomized, Single Blind, Cross-Over Study on the Effect of a Fixed Combination of Citicoline 500 mg Plus Homotaurine 50 mg on Pattern Electroretinogram (PERG) in Patients With Open Angle Glaucoma on Well Controlled Intraocular Pressure.
Retimax
citicoline
glaucoma
homotaurine
neuroprotection
pattern electroretinogram (PERG)
quality of life
visual field
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
02
2022
accepted:
12
04
2022
entrez:
16
5
2022
pubmed:
17
5
2022
medline:
17
5
2022
Statut:
epublish
Résumé
To evaluate the potential beneficial and synergistic effects of oral intake of a fixed combination of citicoline 500 mg plus homotaurine 50 mg (CIT/HOMO) on retinal ganglion cell (RGC) function in subjects with glaucoma using pattern electroretinogram (PERG) and to investigate the effects on visual field and quality of life. Consecutive patients with primary open-angle glaucoma with controlled IOP (<18 mmHg) receiving beta-blockers and prostaglandin analogs alone or as combination therapy (fixed or un-fixed); with stable disease (progression no more than -1 dB/year at the visual field MD); and an early to moderate visual field defect (MD < -12 dB) were randomized to: arm A. topical therapy + CIT/HOMO for 4 months, 2 months of wash out, 4 months of topical therapy alone; arm B. topical therapy alone for 4 months, topical therapy + CIT/HOMO for 4 months, 2 months of wash out. All patients underwent 4 visits: complete ocular examination, visual field, PERG and quality of life assessment (NEI-VFQ25) were performed at each visit. Fifty-seven patients completed the study: 26 in group A and 31 in group B. At the end of the intake period, PERG's P50 and N95 waves recorded a greater amplitude. The increase was statistically significant in the inferior and superior P50 waves amplitude: 0.47 μV (95%CI, 0.02-0.93; Daily oral intake of the fixed combination CIT/HOMO for 4 months improved the function of inner retinal cells recorded by PERG in the inferior and in the superior quadrants, independently from IOP reduction. This interesting association could represent a valid option for practicing neuromodulation in patients with glaucoma to prevent disease progression.
Identifiants
pubmed: 35572982
doi: 10.3389/fmed.2022.882335
pmc: PMC9106378
doi:
Types de publication
Journal Article
Langues
eng
Pagination
882335Informations de copyright
Copyright © 2022 Rossi, Rolle, De Silvestri, Sisto, Mavilio, Mirabile, Paviglianiti, Strano, Picasso, Pasinetti, Milano and Ruberto.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Neurol. 2021 Aug 13;12:724447
pubmed: 34484107
Graefes Arch Clin Exp Ophthalmol. 2008 Aug;246(8):1153-62
pubmed: 18386035
Front Aging Neurosci. 2016 Apr 08;8:73
pubmed: 27092075
J Mol Neurosci. 2003 Feb;20(1):53-60
pubmed: 12663935
Arch Ophthalmol. 2003 Jan;121(1):48-56
pubmed: 12523884
Neural Regen Res. 2019 Mar;14(3):391-394
pubmed: 30539803
Prog Retin Eye Res. 2016 Mar;51:1-40
pubmed: 26113209
Invest Ophthalmol Vis Sci. 1996 Dec;37(13):2651-62
pubmed: 8977479
Prog Brain Res. 2008;173:541-54
pubmed: 18929133
Ann N Y Acad Sci. 1996 Jan 17;777:399-403
pubmed: 8624120
Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30
pubmed: 12049574
Ophthalmologica. 2013;229(4):219-26
pubmed: 23615390
Molecules. 2020 Nov 29;25(23):
pubmed: 33260376
Doc Ophthalmol. 2005 Jan;110(1):91-102
pubmed: 16249960
Ophthalmology. 2005 Mar;112(3):366-75
pubmed: 15745761
Aging Clin Exp Res. 2012 Dec;24(6):580-7
pubmed: 22961121
Int J Mol Sci. 2015 Nov 30;16(12):28401-17
pubmed: 26633368
J Glaucoma. 2003 Jun;12(3):213-20
pubmed: 12782838
Neurochem Res. 2014 Jul;39(7):1206-18
pubmed: 24691765
Am J Ophthalmol. 2000 Oct;130(4):429-40
pubmed: 11024415
J Alzheimers Dis. 2015;50(3):807-16
pubmed: 26757035
Exp Eye Res. 2015 Dec;141:164-70
pubmed: 25998495
Acta Ophthalmol Scand Suppl. 2000;(232):56-7
pubmed: 11235540
Liver Transpl. 2018 Aug;24(8):1070-1083
pubmed: 29679463
Doc Ophthalmol. 1987 Mar;65(3):349-55
pubmed: 3678006
Nutrients. 2020 Mar 18;12(3):
pubmed: 32197303
Adv Exp Med Biol. 2006;583:299-306
pubmed: 17153614
J Clin Med. 2020 Sep 30;9(10):
pubmed: 33007927
Prog Retin Eye Res. 2019 Sep;72:100767
pubmed: 31242454
J Ophthalmic Vis Res. 2016 Apr-Jun;11(2):209-20
pubmed: 27413504
Am J Ophthalmol. 2011 Apr;151(4):671-81
pubmed: 21257146
Curr Neuropharmacol. 2018;16(7):919-932
pubmed: 28676014
Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2411-8
pubmed: 15980229
PLoS One. 2017 Mar 1;12(3):e0171960
pubmed: 28249022
Ophthalmology. 1999 Jun;106(6):1126-34
pubmed: 10366081
Int J Neurosci. 2015;125(12):941-6
pubmed: 25340256
Ophthalmology. 2005 Jan;112(1):10-9
pubmed: 15629814
Cell Mol Life Sci. 2016 Nov;73(22):4279-4297
pubmed: 27333888
CNS Drugs. 2017 Jun;31(6):495-509
pubmed: 28435985
Oxid Med Cell Longev. 2017;2017:2825703
pubmed: 29163753